Kodiak Sciences (KOD) Expected to Post Quarterly Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) is projected to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, analysts expect Kodiak Sciences to post ($3.97) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.

Kodiak Sciences Stock Performance

KOD opened at $107.10 on Tuesday. The firm’s fifty day moving average is $70.95 and its two-hundred day moving average is $44.09. The firm has a market cap of $6.73 billion, a PE ratio of -25.56 and a beta of 2.02. Kodiak Sciences has a twelve month low of $18.05 and a twelve month high of $107.53.

Analyst Ratings Changes

Several brokerages recently commented on KOD. Weiss Ratings downgraded Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. Jefferies Financial Group reissued a “buy” rating and issued a $112.00 target price on shares of Kodiak Sciences in a research note on Monday, September 28th. UBS Group boosted their target price on Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, September 28th. HC Wainwright increased their price target on Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Finally, Lifesci Capital raised their price target on Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.71.

Insider Buying and Selling at Kodiak Sciences

In related news, Director Bros. Advisors Lp Baker bought 807,840 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were acquired at an average price of $72.57 per share, with a total value of $58,624,948.80. Following the completion of the transaction, the director owned 19,121,134 shares in the company, valued at $1,387,620,694.38. The trade was a 4.41% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders bought 2,188,845 shares of company stock valued at $181,326,862. 44.40% of the stock is owned by company insiders.

Kodiak Sciences Company Profile

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss.

Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.

Founded in 2009 and headquartered in Palo Alto, California, Kodiak Sciences is led by founder and Chief Executive Officer Victor Perlroth.